About 23andMe
23andMe is a publicly listed company based in Sunnyvale (United States) founded in 2006 by Linda Avey, and was acquired by TTAM Research Institute in June 2025. Provider of genetic test solutions to study ancestry, genealogy, and inherited traits. 23andMe has raised $943.53 million across 21 funding rounds from investors including Google, Fidelity Investments and Illumina. The company has 562 employees. 23andMe has completed 2 acquisitions, including CureTogether and Icebreaker Health. 23andMe was last valued at $305 million in June 2025. Its website 23andme.com draws about 4.4 million monthly visits. 23andMe offers products and services including Ancestry Service, Health + Ancestry Service, and 23andMe Premium. Its focus areas include HealthTech, Healthcare Booking Platforms, Diagnostics and Internet First Clinical Labs. Its legal entity is 23andMe, Inc. Its competitors include Ancestry, Color and Veritas Genetics; 3 of its 3 listed competitors have raised funding.
Company details
23andMe was founded in 2006 in Sunnyvale, United States, within the biotechnology sector. Genetic testing services are offered through its platform to analyze individual ancestry, genealogy, and inherited traits. User data is collected, categorized, and supplied in searchable formats to researchers and scientists for further study. Operations focus on direct-to-consumer testing and data aggregation, primarily serving the U.S. market.
- Headquarters Sunnyvale, United States
- Employees 562
- Founders Linda Avey
- Stage Acquired
- SectorsHealthcare
- Website category Hobbies and Leisure · Ancestry and Genealogy
- Email••••••••
- Phone•••• ••••
- Website 23andme.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by TTAM Research Institute (Jun 2025)
- Legal Name 23Andme Holding Co.
- Annual Revenue$189.9 M (USD)-13.54as on Mar 31, 2025
- Net Profit-$280.88 M (USD)57.87as on Mar 31, 2025
- EBITDA-$155.85 M (USD)19.44as on Mar 31, 2025
- Total Equity Funding$943.53M (USD)
in 21 rounds
- Latest Funding Round$20M (USD), Post-IPO
Nov 2023
- InvestorsGoogle
& 33 more
- Employee Count562
- Investments & AcquisitionsCureTogether
& 1 more
- Acquired byTTAM Research Institute
(Jun 2025)
Products & Services of 23andMe
23andMe offers a comprehensive portfolio of products and services, including Ancestry Service, Health + Ancestry Service, and 23andMe Premium.
Provides detailed ancestry breakdowns from genetic data.
Offers health insights alongside ancestry reports through genotyping.
Delivers premium reports and features for ongoing genetic health tracking.
Apps and channels of 23andMe
23andMe publishes 2 mobile apps with over 1M+ downloads; its YouTube channel 23andMe has 46.8K subscribers and 30 videos.
Videos from 23andMe
The most watched videos on 23andMe's YouTube channel, 23andMe (46.8K subscribers). Click a video to play it here.
More on 23andMe.
Funding Insights of 23andMe
23andMe has successfully raised a total of $943.53M across 21 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $943.53M
- Total Rounds 21
- Last Round Post-IPO — $20M
- Investors Count 34
Latest 10 of 21 funding rounds of 23andMe with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $20M | Post-IPO | – | – | |
| Dec 2020 | $82.5M | Series F | – | – | |
| Jul 2018 | $300M | Series F | – | GSK | – |
| Aug 2017 | $250M | Series F | – | Sequoia Capital | |
| Apr 2017 | $241,905 | Grant | – | – | |
| Oct 2016 | $1.7M | Grant | – | – | |
| Sep 2016 | $1.76M | Grant | – | – | |
| Apr 2016 | $260,360 | Grant | – | – | |
| Oct 2015 | $115M | Series E | – | Fidelity Investments | |
| Jun 2015 | $79.08M | Series E | – | – | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of 23andMe
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $305M (Jun 2025). 34 investors in total: 32 institutional and 2 angel.
Investors in 23andMe
23andMe has secured backing from 34 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Google, Fidelity Investments and Illumina.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Venture capital investment firm | nvc.vc | Burlingame, United States | ||
Long/short equity hedge fund and VC fim | altimeter.com | Boston, United States | ||
Family office of Wallenburg family | wallenberg.org | Stockholm, Sweden | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Multiple sectors are invested in by this single-family office. | euclideancapital.tcc.mode | New York, United States | ||
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Early-stage venture capital funding is provided by Xfund. | xfund.com | Cambridge, United States |
Investor details for 23andMe
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of 23andMe
50 people are tracked at 23andMe (19 in leadership, 5 in board & advisors, 26 in team); the tracked headcount is 562.
| Name | Role | Group |
|---|---|---|
Linda Avey | Founder | Leadership |
Lisa Isaacson | Director of Accounting | Leadership |
Daniel Brakin | Director, Growth Marketing | Leadership |
Frank Russo | Chief Security Officer | Leadership |
CJ Swenson | Director, Marketing, Acquisition, Retail & International | Leadership |
Joe Selsavage | Interim Chief Executive Officer and Chief Financial and Accounting Officer | Leadership |
Kael Reicin | CFO, Research Institute | Leadership |
Evan Minnick | Director, Financial Planning & Analysis (fp&a) | Leadership |
Huey W. | Director, Internal Controls & Compliance | Leadership |
Kristen Quint | Chief Of Staff, Office Of CEO | Leadership |
Shana Ryan | Director, Integrated Brand Marketing, Design & Advertising Operations | Leadership |
Antoine P. | Director, Security And Compliance | Leadership |
David Buckingham | Head Of Intellectual Property | Leadership |
Matt Kvarda | Chief Restructuring Officer | Leadership |
Tracy Keim | CMO | Leadership |
Guy Chayoun | VP, General Counsel and Corporate Secretary | Leadership |
Hao Cui | Director Of Accounting | Leadership |
Sue Nallapeta | VP, Engineering | Leadership |
Alan Spector | Director, Engineering | Leadership |
Jim Frankola | Director | Board & advisors |
30 more people are available in the full profile.
Complete people profiles for 23andMe
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of 23andMe
23andMe is a publicly listed company on the OTC with ticker symbol MEHCQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jun 2021
- Listed onNASDAQ: ME
- Listed entity23andMe Holding Co.
- Exchange sectorHealth technology
- ISINUS90138Q3065
- Share price$3.60 (+0.56% on the day) · 2025-12-05
- Market capitalisation$91.6M
- EPS (diluted, trailing year)$-8.82
- Volume (last session)64,454
- Analyst consensusNeutral
Financials of 23andMe
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $189.9M | -$280.9M | -$155.8M |
| 2023 | $219.6M | -$666.7M | -$193.5M |
| 2022 | $299.5M | -$311.7M | -$287.5M |
| 2021 | $271.9M | -$217.5M | -$218.6M |
| 2020 | $243.9M | -$183.6M | -$164.9M |
Detailed financial statements for 23andMe
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 23andMe
23andMe has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CureTogether and Icebreaker Health.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of remote patient consultation services and online delivery of medical care products | lemonaidhealth.com | San Francisco, United States | 2014 | Oct 2021 | $400M | |
Quantitative data on medical conditions is shared by users online. | curetogether.com | Mountain View, United States | 2008 | Jul 2012 | •••• |
Complete acquisition details for 23andMe
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of 23andMe
9 dated milestones of 23andMe across 19 years, from founding to its latest funding, stage changes and deals.
- Founded 23andMe is founded.
- Funding First funding round.
- Acquisition Acquires CureTogether.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Icebreaker Health.
- Funding Latest funding round, Post-IPO, of $20.0M.
- Milestone Reaches Soonicorn status.
- Exit Acquired by TTAM Research Institute.
Competitors of 23andMe
23andMe has 3 listed competitors in our database, 3 of them funded. They include Ancestry, Color and Veritas Genetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ancestry.com | 1996 | Lehi, United States | $146.2M | 1,228 | Provider of an online genealogy platform offering a host of services | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| veritasgenetics.com | 2014 | Danvers, United States | $53.38M | 14 | Genetic testing products for health risks and traits are offered. |
Detailed competitors of 23andMe
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of 23andMe
The website of 23andMe (23andme.com) receives about 4.4M visits a month and ranks #8,883 among all websites worldwide, #45 in Ancestry and Genealogy.
- Monthly visits4.4M
▼ 4.2% vs previous month
- Unique visitors2.1M
per month
- Global rank#8,883
among all websites
- Category rank#45
Hobbies and Leisure · Ancestry and Genealogy
- Bounce rate29%
- Pages per visit6.4
- Average visit4 min 31 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with 23andMe. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ancestry.com | 100% | 37.5M | #497 | View details | |
| familytreedna.com | 98% | #34,420 | View details | ||
| myheritage.com | 82% | 12.2M | #2,869 | View details | |
| genomelink.io | 71% | 1M | #39,195 | View details | |
wikitree.com | wikitree.com | 70% | #10,303 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for 23andMe
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as 23andMe (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about 23Andme
Complete news archive for 23andMe
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 23andMe
23andMe was founded in 2006 and raised its 1st funding round 1 year after it was founded.
23andMe is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
23andMe is a funded company, having raised a total of $943.53M across 21 funding rounds to date. The company's 1st funding round was a Series E of $79.08M, raised on May 2007.
23andMe has 562 employees.
Annual revenue of 23andMe is $189.9M as on Mar 31, 2025.
23andMe was founded in 2006 in Sunnyvale, United States, within the biotechnology sector. Genetic testing services are offered through its platform to analyze individual ancestry, genealogy, and inherited traits. User data is collected, categorized, and supplied in searchable formats to researchers and scientists for further study. Operations focus on direct-to-consumer testing and data aggregation, primarily serving the U.S. market.
23andMe's top competitors include Ancestry, Veritas Genetics and Color.
23andMe offers Ancestry Service, Health + Ancestry Service, and 23andMe Premium.
Yes, 23andMe is publicly traded on OTC under the ticker symbol MEHCQ.
23andMe has made 2 acquisitions, including CureTogether, and Icebreaker Health.
23andMe has 34 investors. Key investors include Google, Fidelity Investments, Illumina, NIH, and HHS.
The valuation of 23andMe is $305M as of Jun 2025.